The combined firm is expected to develop a portfolio of clinical-stage candidates targeting Types 1 and 2 diabetes and coeliac disease.
US-based clinical-stage biopharmaceutical company Barinthus Biotherapeutics has performed a reverse…
US-based clinical-stage biopharmaceutical company Barinthus Biotherapeutics has performed a reverse…